Meeting
2023 ASCO Annual Meeting
Modified FOLFOXIRI plus cetuximab and avelumab as initial therapy in RAS wild-type unresectable metastatic colorectal cancer: Results of the phase II AVETRIC trial by GONO.
Authors
Veronica Conca
Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy and Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy, Pisa, Italy, Italy
Veronica Conca , Carlotta Antoniotti , Francesca Bergamo , Filippo Pietrantonio , Daniele Rossini , Mario Scartozzi , Eleonora Perissinotto , Alberto Giovanni Leone , Pusceddu Valeria , Beatrice Borelli , Luigi Cavanna , Tiziana Pia Latiano , Daniele Santini , Gianluca Masi , Lisa Salvatore , Luca Frassineti , Francesco Leone , Stefano Tamberi , Luca Boni , Chiara Cremolini
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT04513951
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3575)
DOI
10.1200/JCO.2023.41.16_suppl.3575
Abstract #
3575
Poster Bd #
275
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Modified (m)-FOLFOXIRI plus cetuximab versus m-FOLFOXIRI plus bevacizumab as initial treatment of patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer: Survival analysis of the phase II randomized DEEPER trial by JACCRO.
First Author: Yu Sunakawa
Poster
2024 ASCO Gastrointestinal Cancers Symposium
HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer (mCRC) refractory to anti-EGFR antibodies.
First Author: Atsushi Ishiguro
Poster
2023 ASCO Annual Meeting
A multicenter randomized phase II trial comparing CAPOXIRI + bevacizumab with FOLFOXIRI + bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Primary results of the QUATTRO-II study.
First Author: Hideaki Bando
Poster
2021 Gastrointestinal Cancers Symposium
Safety analysis of the randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with RAS wild-type tumors: The DEEPER trial (JACCRO CC-13).
First Author: Takanori Watanabe